With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...

Scientists have engineered a highly selective catalyst that can convert methane, a major component of natural gas, into methanol, an easily transportable liquid fuel, in a single, one-step reaction.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

CHICAGO (AP) — Two bald eagles hatchlings have been spotted in a nest in a Chicago park in what city officials believe is the raptors' first successful wild breeding in the Windy City in more than a ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Italian company Angelini Pharma ...

Angelini Pharma has agreed to acquire all outstanding shares of Catalyst Pharmaceuticals (CPRX) for $31.50 per share in cash, for a total equity value of approximately $4.1B. The deal has been ...